Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence

Prostate

Volumn 69, Issue 8, 2009, Pages 886-894

  Svatek, Robert S ^a,e   Jeldres, Claudio ^b   Karakiewicz, Pierre I ^b   Suardi, Nazareno ^b,c   Walz, Jochen ^b   Roehrborn, Claus G ^a   Montorsi, Francesco ^c   Slawin, Kevin M ^d   Shariat, Shahrokh F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e NONE   (United States)

Author keywords

Marker; Nomogram; Prediction; Prostatic neoplasms; Radical prostatectomy; Recurrence

Indexed keywords

BIOLOGICAL MARKER; ENDOGLIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 SOLUBLE RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PROSTATE SPECIFIC ANTIGEN;

ACCURACY; ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMISTRY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECURRENT DISEASE; RELAPSE; BIOPSY; BLOOD; CANCER STAGING; COHORT ANALYSIS; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; BIOPSY; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; RECEPTORS, INTERLEUKIN-6; RECURRENCE; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; VASCULAR CELL ADHESION MOLECULE-1;

EID: 65549127138     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20938     Document Type: Article

References (26)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA: Cancer J clin 2008;58(2):71-96.
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169(2):517-523. (Pubitemid 36132976)
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. Jama 1999;281(17):1591-1597. (Pubitemid 29211767)
4. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Jama 2005;294(4):433-439. (Pubitemid 41124175)
5. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Marechal JM, Scalliet P, Haustermans K, Pierart M. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005; 366(9485):572-578.
6. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341(24):1781-1788.
7. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby- Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized clinical trial. JAMA 2006;296(19):2329-2335.
8. Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ Jr, Dotan ZA, DiBlasio CJ, Reuther A, Klein EA, Kattan MW. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23(28): 7005-7012. (Pubitemid 46260287)
9. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17(5):1499-1507. (Pubitemid 29220858)
10. Chun FK, Briganti A, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, Walz J, Eichelberg C, Salomon G, Haese A, Currlin E, Ahyai SA, Benard F, Huland H, Graefen M, Karakiewicz PI. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer 2007;43(3):536-543. (Pubitemid 46177590)
11. Gallina A, Karakiewicz PI, Hutterer GC, Chun FK, Briganti A, Walz J, Antebi E, Shariat SF, Suardi N, Graefen M, Erbersdobler A, Salonia A, Rigatti P, Huland H, Montorsi F. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer 2007; 121(4):791-795.
12. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95(9): 634-635. (Pubitemid 36603708)
13. Kattan MW, Shariat SF, Andrews B, Zhu K, Canto E, Matsumoto K, Muramoto M, Scardino PT, Ohori M, Wheeler TM, Slawin KM. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. J Clin Oncol 2003;21(19): 3573-3579. (Pubitemid 46594048)
14. Shariat SF, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol 2007; 3(4):449-461. (Pubitemid 47260286)
15. Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001;58(6):1008-1015. (Pubitemid 34017290)
16. Shariat SF, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004;22(9):1655-1663. (Pubitemid 41079804)
17. Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004;10(6):1992-1999.
18. Shariat SF, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 2007;25(4):349-355. (Pubitemid 350002982)
19. Shariat SF, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) (tgf-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19(11):2856-2864.
20. Henson DE, Hutter RV, Farrow G. Practice protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. A publication of the cancer committee, college of American pathologists. Task Force on the Examination of Specimens Removed From Patients With Prostate Cancer. Arch Pathol Lab Med 1994;118(8):779-783.
21. Shariat SF, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001; 92(12):2985-2992.
22. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15(4):361-387.
23. Begg CB, Cramer LD, Venkatraman ES, Rosai J. Comparing tumour staging and grading systems:A case study and a review of the issues, using thymoma as a model. Stat Med 2000; 19(15):1997-2014.
24. Atkinson AC. A note on the generalized information criterion for choice of a model. Biometrika 1980;67:413-418.
25. Van Houwelingen JC, Le Cessie S. Predictive value of statistical models. Stat Med 1990;9(11):1303-1325. (Pubitemid 20361741)
26. Shariat SF, Canto EI, Kattan MW, Slawin KM. Beyond prostatespecific antigen: New serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 2004; 6(2):58-72.